The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06246-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Yuting Yan und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Nature Science Foundation of China, Tianjin Health Science and Technology Project, Tianjin Health Research Project.
Abstract (Originalsprache)
Recent advances in measurable residual disease (MRD) technology have significantly enhanced predictive accuracy for outcomes in various hematologic malignancies, serving as a crucial surrogate endpoint. However, in mantle cell lymphoma (MCL), identifying the optimal timing for MRD assessment and understanding the prognostic implications of MRD dynamics remain challenging, primarily due to limited extensive MRD data. Our study encompassed 102 patients with MCL, all presenting with clonal B-cell involvement in bone marrow as determined by multiparametric flow cytometry (MFC). MRD evaluations were conducted every two cycles. 75.5% (77/102) achieved MRD negativity during induction therapy. We found the MRD status at the end of four cycles treatment had the best predictive ability for survival (HR = 3.2, C-index = 0.664). 32 of 77 patients (41.6%) had a rapid tumor burden reduction and achieved MRD negativity within two cycles treatment. Notably, this swift shift to MRD negativity was observed more frequently in patients classified as MIPI high-risk. However, this rapid clearance of MRD did not confer any prognostic benefit to these patients. Subgroup analyses revealed that MRD negativity held prognostic value in almost all categories, except for those with blastoid/pleomorphic morphology. MRD assessment serves as a valuable complement to the traditional response evaluation, particularly benefiting for patients attaining partial remission. These findings highlighted the importance of MRD detection during response evaluation of MCL therapy and determined that after four treatment cycles is the best MRD detection timepoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
- , 288 Nanjing Road, Tianjin, 30020, China.
- Tianjin Institutes of Health Science, Tianjin, China. qiulg@ihcams.ac.cn.
- , 288 Nanjing Road, Tianjin, 30020, China. qiulg@ihcams.ac.cn.
- Tianjin Institutes of Health Science, Tianjin, China. yishuhua@ihcams.ac.cn.
Förderung
- the National Nature Science Foundation of China
- Tianjin Health Science and Technology Project
- Tianjin Health Research Project
- the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Yan, Y., Huang, Y., Yu, Y., Duan, Z., Li, Y., Lyu, R., Wang, T., Xiong, W., Wang, Y., Wang, Q., Liu, W., An, G., Sui, W., Xu, Y., Huang, W., Hao, M., Zou, D., Qiu, L., & Yi, S. (2025). The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-025-06246-9
Vancouver
Yan Y, Huang Y, Yu Y, Duan Z, Li Y, Lyu R, et al. The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma. Annals of Hematology. 2025. doi:10.1007/s00277-025-06246-9
BibTeX
@article{Yan2025,
author = {Yan, Yuting and Huang, Yanshan and Yu, Ying and Duan, Zhongchao and Li, Yuxi and Lyu, Rui and Wang, Tingyu and Xiong, Wenjie and Wang, Yi and Wang, Qi and Liu, Wei and An, Gang and Sui, Weiwei and Xu, Yan and Huang, Wenyang and Hao, Mu and Zou, Dehui and Qiu, Lugui and Yi, Shuhua},
title = {The optimal time and clinical implications of measurable residual disease detection in mantle cell lymphoma},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06246-9}
}
EUVIMED